Efficacy, safety, tolerability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study.

被引：0
|
作者：
Bitzer, Michael
Horger, Marius
Ganten, Tom M.
Lauer, Ulrich M.
Woerns, Marcus A.
Siveke, Jens T.
Dollinger, Matthias M.
Gerken, Guido
Wege, Henning
Giannini, Edoardo G.
Zagonel, Vittorina
Cillo, Umberto
Trevisani, Franco
Santoro, Armando
Montesarchio, Vincenzo
Hauns, Bernhard
Asche, Julia
Jankowsky, Ruediger
Mais, Anna
Hentsch, Bernd
机构：
[1] Univ Tubingen, Med Univ Clin, Tubingen, Germany
[2] Univ Tubingen, Tubingen, Germany
[3] Heidelberg Univ, Dept Internal Med, Heidelberg, Germany
[4] Med Univ Clin, Mainz, Germany
[5] Tech Univ Munich, Dept Internal Med 2, D-80290 Munich, Germany
[6] Univ Halle Wittenberg, Dept Internal Med, D-06108 Halle, Germany
[7] Univ Duisburg Essen, Dept Gastroenterol & Hepatol, Essen, Germany
[8] Univ Hosp Hamburg Eppendorf, Hamburg, Germany
[9] Univ Genoa, Dept Internal Med, Gastroenterol Unit, I-16126 Genoa, Italy
[10] Ist Oncol Veneto IRCCS, Padua, Italy
[11] Azienda Univ Padova, Hepatobiliary Surg & Liver Transplant Unit, Padua, Italy
[12] Univ Bologna, Bologna, Italy
[13] Humanitas Canc Ctr, Dept Oncol, Rozzano, Italy
[14] UO Oncol Osped Cotugno Napoli, Naples, Italy
[15] 4SC AG, Planegg Martinsried, Germany
[16] 4SC AG, Martinsried, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4115
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase I/II study of capecitabine combined with peginterferon alfa-2a in sorafenib-refractory advanced hepatocellular carcinoma patients
    Ogasawara, Sadahisa
    Chiba, Tetsuhiro
    Ooka, Yoshihiko
    Kanogawa, Naoya
    Motoyama, Tenyu
    Suzuki, Eiichiro
    Tawada, Akinobu
    Kanai, Fumihiko
    Yokosuka, Osamu
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [22] A phase I/II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC)
    Yopp, Adam Charles
    Singal, Amit G.
    Arriaga, Yull Edwin
    Verma, Udit N.
    Shan, Joseph
    Kallinteris, Nikoletta L.
    Beg, Muhammad Shaalan
    Mansour, John C.
    Zhu, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] Efficacy and safety of nintedanib vs sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomised Phase II trial
    Yen, C.
    Kim, T. Y.
    Feng, Y. H.
    Chao, Y.
    Lin, D. Y.
    Studeny, M.
    Hocke, J.
    Huang, D. C. L.
    Ryoo, B. Y.
    Cheng, A. L.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S612 - S612
  • [24] Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Palmer, Daniel H.
    Ma, Yuk Ting
    Peck-Radosavljevic, Markus
    Ross, Paul J.
    Graham, Janet Shirley
    Fartoux, Laetitia
    Deptala, Andrzej
    Wenz, Arne
    Hocke, Julia
    Loembe, Arsene-Bienvenu
    Meyer, Tim
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [25] A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma
    Ogasawara, Sadahisa
    Chiba, Tetsuhiro
    Ooka, Yoshihiko
    Kanogawa, Naoya
    Motoyama, Tenyu
    Suzuki, Eiichiro
    Tawada, Akinobu
    Kanai, Fumihiko
    Yokosuka, Osamu
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (04) : 762 - 768
  • [26] Efficacy and safety of a phase II study of sorafenib plus gemcitabine in advanced hepatocellular carcinoma.
    Srimuninnimit, V.
    Sriuranpong, V.
    Suwanvecho, S.
    Soparattanapaisarn, N.
    Ithimakin, S.
    Akewanlop, C.
    Tanasanvimon, S.
    Parinyanitikul, N.
    Kiatikajornthada, N.
    Suwanrusme, H.
    Chaiyarat, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] Preliminary efficacy and safety of perioperative treatment of camrelizumab combined with apatinib in resectable hepatocellular carcinoma (HCC): A prospective phase II study.
    Xia, Yongxiang
    Wang, Ping
    Pu, Liyong
    Qian, Xiaofeng
    Cheng, Feng
    Wang, Ke
    Zhang, Chuanyong
    Li, Donghua
    Li, Xiangcheng
    Zhang, Feng
    Zhao, Jie
    Li, Si
    Xi, Wenjing
    Wang, Xuehao
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma
    Sadahisa Ogasawara
    Tetsuhiro Chiba
    Yoshihiko Ooka
    Naoya Kanogawa
    Tenyu Motoyama
    Eiichiro Suzuki
    Akinobu Tawada
    Fumihiko Kanai
    and Osamu Yokosuka
    Investigational New Drugs, 2014, 32 : 762 - 768
  • [29] EFFICACY AND SAFETY OF SORAFENIB AND CRYOTHERAPY FOR ADVANCED HEPATOCELLULAR CARCINOMA (HCC): A SINGLE CENTER RANDOMIZED STUDY
    Yang, Yongping
    Lu, Yinying
    Wang, Chunping
    Qu, Jianhui
    Chang, Xiujuan
    An, Linjing
    Hu, Ke-Qin
    HEPATOLOGY, 2011, 54 : 1367A - 1367A
  • [30] Efficacy and safety of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomized phase II trial.
    Cheng, Ann-Lii
    Yen, Chia-Jui
    Kim, Tae-You
    Feng, Yin-Hsun
    Chao, Yee
    Lin, Deng-Yn
    Loembe, Arsene-Bienvenu
    Hocke, Julia
    Choi, Caren
    Ryoo, Baek-Yeol
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
12345